{"title": "Multidisciplinary: vaccines - European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-vaccines", "hostname": "europa.eu", "description": "Multidisciplinary: vaccines", "sitename": "European Medicines Agency", "date": "2018-09-17", "cleaned_text": "Medicines Agency's scientific guidelines on vaccines help medicine developers prepare marketing-authorisation applications for human medicines. For a complete list of scientific guidelines currently open for consultation, see [Public consultations](/en/news-events/open-consultations). Guidelines [Adjuvants in vaccines for human use - Scientific guideline](https://www.ema.europa.eu/en/adjuvants-vaccines-human-use-scientific-guideline) [Clinical evaluation of new vaccines - Scientific guideline](https://www.ema.europa.eu/en/clinical-evaluation-new-vaccines-scientific-guideline) [Development of vaccinia virus-based vaccines against smallpox - Scientific guideline](https://www.ema.europa.eu/en/development-vaccinia-virus-based-vaccines-against-smallpox-scientific-guideline) [Dossier structure and content for pandemic-influenza-vaccine marketing-authorisation application - Scientific guideline](https://www.ema.europa.eu/en/dossier-structure-content-pandemic-influenza-vaccine-marketing-authorisation-application-scientific) [EMA considerations on COVID-19 vaccine approval - Scientific guideline](https://www.ema.europa.eu/en/ema-considerations-covid-19-vaccine-approval-scientific-guideline) [Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza vaccines - Scientific guideline](https://www.ema.europa.eu/en/explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines-scientific) [Influenza vaccines - non-clinical and clinical module - Scientific guideline](https://www.ema.europa.eu/en/influenza-vaccines-non-clinical-clinical-module-scientific-guideline) [Influenza vaccines - quality module - Scientific guideline](https://www.ema.europa.eu/en/influenza-vaccines-quality-module-scientific-guideline) [Influenza vaccines - submission and procedural requirements - Scientific guideline](https://www.ema.europa.eu/en/influenza-vaccines-submission-procedural-requirements-scientific-guideline) [Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context - Scientific guideline](https://www.ema.europa.eu/en/influenza-vaccines-prepared-viruses-potential-cause-pandemic-intended-use-outside-core-dossier) [Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU - Scientific guideline](https://www.ema.europa.eu/en/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu-scientific-guideline) [Quality aspects included in the product information for vaccines for human use - Scientific guideline](https://www.ema.europa.eu/en/quality-aspects-included-product-information-vaccines-human-use-scientific-guideline) [Preclinical pharmacological and toxicological testing of vaccines - Scientific guideline](https://www.ema.europa.eu/en/preclinical-pharmacological-toxicological-testing-vaccines-scientific-guideline) [Quality aspects on the isolation of candidate influenza vaccine viruses in cell culture - Scientific guideline](https://www.ema.europa.eu/en/quality-aspects-isolation-candidate-influenza-vaccine-viruses-cell-culture-scientific-guideline) [Quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines - Scientific guideline](https://www.ema.europa.eu/en/quality-non-clinical-clinical-aspects-live-recombinant-viral-vectored-vaccines-scientific-guideline) [Scientific data requirements for a vaccine antigen master file - Scientific guideline](https://www.ema.europa.eu/en/scientific-data-requirements-vaccine-antigen-master-file-scientific-guideline) [Testing for simian virus 40 (SV40) in polio virus vaccines - Scientific guideline](https://www.ema.europa.eu/en/testing-simian-virus-40-sv40-polio-virus-vaccines-scientific-guideline) [Treatment and prophylaxis of respiratory syncytial virus (RSV) disease Scientific guideline](https://www.ema.europa.eu/en/treatment-prophylaxis-respiratory-syncytial-virus-rsv-disease-scientific-guideline) [Viral safety of oral poliovirus vaccine (OPV) - Scientific guideline](https://www.ema.europa.eu/en/viral-safety-oral-poliovirus-vaccine-opv-scientific-guideline) Reflection papers [Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 - Scientific guideline](https://www.ema.europa.eu/en/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2) Points to consider Concept papers [Stability and traceability requirements for vaccine intermediates - Scientific guideline](https://www.ema.europa.eu/en/stability-traceability-requirements-vaccine-intermediates-scientific-guideline) [DNA vaccines](https://www.ema.europa.eu/en/dna-vaccines) Questions and answers [Questions and answers on the Haemagglutination Inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - Scientific guideline](https://www.ema.europa.eu/en/questions-answers-haemagglutination-inhibition-hi-test-qualification-influenza-vaccine-inactivated) [Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Scientific guideline](https://www.ema.europa.eu/en/questions-answers-bovine-spongiform-encephalopathies-bse-vaccines-scientific-guideline) Public statements and position papers [Evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines - Scientific guideline](https://www.ema.europa.eu/en/evaluation-bovine-spongiform-encephalopathies-bse-risk-use-materials-bovine-origin-during-0) [Thiomersal in vaccines for human use - recent evidence supports safety of thiomersal-containing vaccines - Scientific guideline](https://www.ema.europa.eu/en/thiomersal-vaccines-human-use-recent-evidence-supports-safety-thiomersal-containing-vaccines) [Thiomersal: implementation of the warning statement relating "}